Sernova Corp (SEOVF) 0.1260 $SEOVF
Sernova Provides Corporate Update
Marketwire Canada - Mon Nov 10, 5:35AM CST
Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing cell therapy technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and hemophilia, today provides a corporate update, summarizing advances made in the clinical development of its Cell Pouch(TM) over the past 12 months and the application of its technologies to new disease indications.
SVA.VN: 0.155 (-0.005)
PMT, BPOPM, EXAS, SVA, SGG Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Perpetual Energy Inc (NYSE
MT), Popular Capital Trust II (NASDAQ:BPOPM), Exact Sciences Corp (NASDAQ:EXAS), Sernova Corp (NASDAQ:SVA), SnipGold Corp (NYSE:SGG) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SGG: 37.65 (-0.04), PMT: 21.90 (-0.19), EXAS: 27.60 (+0.39), SVA: 4.95 (+0.07), BPOPM: 21.31 (+0.51)
Sernova Agrees on Terms to Gain Access to Proprietary Stem Cell Technology For the Treatment of Diabetes
Marketwire - Tue Jul 15, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases announced today it has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes.
SVA.VN: 0.155 (-0.005)
Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego
Marketwire - Tue Jun 24, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia announced today that it is participating at the US BIO International Convention in San Diego, June 23-26th.
SVA.VN: 0.155 (-0.005)
Sernova's CEO Dr. Philip Toleikis Featured on BNN
Marketwire - Fri Jun 20, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia today was featured on BNN by news anchor Francis Horodelski.
SVA.VN: 0.155 (-0.005)
Fission 3 Grants Stock Options
Marketwire - Fri Jan 31, 2:46PM CST
FISSION 3.0 CORP. ("Fission 3"
(TSX VENTURE: FUU) announces that it has granted incentive stock options to Directors, Officers, employees and consultants entitling them to purchase up to 14,000,000 shares in the capital of the Company subject to the policies of the TSX Venture Exchange. The options are exercisable until January 31, 2019 at a price of $0.155 per share.
FUU.VN: 0.080 (+0.005), UTMD: 58.85 (+0.52)
Sernova Provides Corporate Update
Marketwire Canada - Mon Nov 10, 5:35AM CST
Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing cell therapy technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and hemophilia, today provides a corporate update, summarizing advances made in the clinical development of its Cell Pouch(TM) over the past 12 months and the application of its technologies to new disease indications.
SVA.VN: 0.155 (-0.005)
PMT, BPOPM, EXAS, SVA, SGG Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Perpetual Energy Inc (NYSE
MT), Popular Capital Trust II (NASDAQ:BPOPM), Exact Sciences Corp (NASDAQ:EXAS), Sernova Corp (NASDAQ:SVA), SnipGold Corp (NYSE:SGG) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: SGG: 37.65 (-0.04), PMT: 21.90 (-0.19), EXAS: 27.60 (+0.39), SVA: 4.95 (+0.07), BPOPM: 21.31 (+0.51)
Sernova Agrees on Terms to Gain Access to Proprietary Stem Cell Technology For the Treatment of Diabetes
Marketwire - Tue Jul 15, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases announced today it has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes.
SVA.VN: 0.155 (-0.005)
Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego
Marketwire - Tue Jun 24, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia announced today that it is participating at the US BIO International Convention in San Diego, June 23-26th.
SVA.VN: 0.155 (-0.005)
Sernova's CEO Dr. Philip Toleikis Featured on BNN
Marketwire - Fri Jun 20, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia today was featured on BNN by news anchor Francis Horodelski.
SVA.VN: 0.155 (-0.005)
Fission 3 Grants Stock Options
Marketwire - Fri Jan 31, 2:46PM CST
FISSION 3.0 CORP. ("Fission 3"
(TSX VENTURE: FUU) announces that it has granted incentive stock options to Directors, Officers, employees and consultants entitling them to purchase up to 14,000,000 shares in the capital of the Company subject to the policies of the TSX Venture Exchange. The options are exercisable until January 31, 2019 at a price of $0.155 per share. FUU.VN: 0.080 (+0.005), UTMD: 58.85 (+0.52)
